Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IgG4

IgG4

Brief Information

Name:Immunoglobulin G
Target Synonym:Immunoglobulin G
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Synonym Name

Background

ADE has been observed in SARS, MERS and other human respiratory virus infections, which suggests a real risk of ADE for SARS-CoV-2 vaccines and antibody-based interventions. Non-neutralizing mAbs against SARS-CoV-2 should be administered to determine whether non-neutralizing antibodies enhance disease.

Clinical and Translational Updates

    Public Drug Information

    Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
    Imlifidase Mac-1 Approved Hansamed Inc Idefirix EU Rejection of renal transplantation Hansa Biopharma Ab 2020-08-25 Rejection of renal transplantation; Purpura, Thrombotic Thrombocytopenic; Kidney Diseases; Rejection of organ transplantation; Guillain-Barre Syndrome; Renal Insufficiency, Chronic; Kidney Failure, Chronic Details

    Clinical Drug Information

    Name Research Code Research Phase Company Indications Clinical Trials
    Recombinant Tumor Enzyme Specific Interferon α-2b Fc Fusion (Livzon Pharmaceutical Group) A-01 Phase 1 Clinical Livzon Pharmaceutical Group Inc Solid tumours Details
    Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) Phase 1 Clinical University Of California San Diego Leukemia, Myeloid, Acute Details

    This web search service is supported by Google Inc.

    totop
    Call us
    Call us
    North America: +1 800-810-0816 (Toll Free)
    Asia & Pacific: +86 400-682-2521
    Fax
    Fax
    +1 888-377-6111
    Address
    Address
    1 Innovation Way, Newark, DE 19711, USA

    Leave a message